Abstract
Patients with diabetes exhibit significantly altered renin-angiotensin system (RAS) control. Recently, it has been determined that hyperglycemic conditions induce an increase in angiotensin II (AT II) expression; specifically by cardiomyocytes. Altered RAS has been shown to be associated with an increase in oxidative stress and cardiac dysfunction leading to the development of cardiac hypertrophy. The transient outward potassium current (Ito) in cardiac myocytes is mainly mediated by members of the Kv subfamily of voltage gated potassium channels and has been shown to be altered in cellular localization and expression during the development of cardiac hypertrophy. However it is not clear as to how AT II affects the pore forming complex at the cell membrane and thus directly affects the Ito current. In the current study, we explored the protective effect of PPARγ ligands on cardiomyocyte Ito by preventing NADPH Oxidase activation and the ensuing ROS formation. Furthermore, short term PPARγ activation in diabetic leptin deficient db/db mice displayed improvements in the membrane association of the molecular components of Ito as well as prolonged QT interval. These findings demonstrate that PPARγ agonists have the potential to attenuate cardiomyocyte dysfunction associated with diabetes.
Keywords: Diabetes, cardiac remodeling, PPARγ; transient outward potassium channel current, Ito.
Current Pharmaceutical Design
Title:PPARγ Activation Improves the Molecular and Functional Components of Ito Remodeling by Angiotensin II
Volume: 19 Issue: 27
Author(s): Gayani Nanayakkara, Nilmini Viswaprakash, Juming Zhong, Thiruchelvan Kariharan, John Quindry and Rajesh Amin
Affiliation:
Keywords: Diabetes, cardiac remodeling, PPARγ; transient outward potassium channel current, Ito.
Abstract: Patients with diabetes exhibit significantly altered renin-angiotensin system (RAS) control. Recently, it has been determined that hyperglycemic conditions induce an increase in angiotensin II (AT II) expression; specifically by cardiomyocytes. Altered RAS has been shown to be associated with an increase in oxidative stress and cardiac dysfunction leading to the development of cardiac hypertrophy. The transient outward potassium current (Ito) in cardiac myocytes is mainly mediated by members of the Kv subfamily of voltage gated potassium channels and has been shown to be altered in cellular localization and expression during the development of cardiac hypertrophy. However it is not clear as to how AT II affects the pore forming complex at the cell membrane and thus directly affects the Ito current. In the current study, we explored the protective effect of PPARγ ligands on cardiomyocyte Ito by preventing NADPH Oxidase activation and the ensuing ROS formation. Furthermore, short term PPARγ activation in diabetic leptin deficient db/db mice displayed improvements in the membrane association of the molecular components of Ito as well as prolonged QT interval. These findings demonstrate that PPARγ agonists have the potential to attenuate cardiomyocyte dysfunction associated with diabetes.
Export Options
About this article
Cite this article as:
Nanayakkara Gayani, Viswaprakash Nilmini, Zhong Juming, Kariharan Thiruchelvan, Quindry John and Amin Rajesh, PPARγ Activation Improves the Molecular and Functional Components of Ito Remodeling by Angiotensin II, Current Pharmaceutical Design 2013; 19 (27) . https://dx.doi.org/10.2174/1381612811319270006
DOI https://dx.doi.org/10.2174/1381612811319270006 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mast Cells and Inflammatory Heart Disease: Potential Drug Targets
Cardiovascular & Hematological Disorders-Drug Targets Sex Differences in Alcohol Use Disorder
Current Medicinal Chemistry Emerging Molecular Targets for Treatment of Erectile Dysfunction: Vascular and Regenerative Therapies on the Horizon
Current Drug Targets Genetic Privacy in Sports: Clearing the Hurdles
Recent Patents on DNA & Gene Sequences The Clinical Problems of Hypertension Treatment in Hemodialysis Patients
Current Vascular Pharmacology Editorial (Thematic Issue: The Long Way to a Successful Medical Therapy of Heart Failure with Beta-blockers in Children with Heart Disease)
Reviews on Recent Clinical Trials The Role of Fibrate Treatment in Dyslipidemia: An Overview
Current Pharmaceutical Design Molecular Aspects of Modulation of L-type Calcium Channels by Protein Kinase C
Current Molecular Pharmacology Diabetic Retinopathy and Atherosclerosis: is there a Link?
Current Diabetes Reviews Recent Developments in Nanoparticle Based Targeted Delivery of Chemotherapeutics
Current Bioactive Compounds Neurodevelopmental Delay and Intellectual Disability in Pediatric Heart Transplant
Current Psychiatry Reviews Cross Talk between the Cardiovascular and Nervous Systems:Neurotrophic Effects of Vascular Endothelial Growth Factor (VEGF) and Angiogenic Effects of Nerve Growth Factor (NGF)-Implications in Drug Development
Current Pharmaceutical Design Metformin and Anti-Cancer Therapeutics: Hopes for a More Enhanced Armamentarium Against Human Neoplasias?
Current Medicinal Chemistry Targeting SUMOylation Cascade for Diabetes Management
Current Drug Targets A Review of the Pharmacological Properties of 3,4-dihydro-2(1H)- quinolinones
Mini-Reviews in Medicinal Chemistry Anti-T. cruzi Agents: Our Experience in the Evaluation of More than Five Hundred Compounds
Mini-Reviews in Medicinal Chemistry Drugs as Possible Triggers of Takotsubo Cardiomyopathy: A Comprehensive Literature Search - Update 2015
Current Clinical Pharmacology Trimetazidine: Does it Actually Reduce QT Dispersion After First Acute Myocardial Infarction?
Current Drug Therapy Therapeutic Potential of Targeting Protease Activated Receptors in Cardiovascular Diseases
Current Pharmaceutical Design Patent Selections:
Recent Patents on Cardiovascular Drug Discovery